SCHEMBL2092622

SCHEMBL2092622

[CH2]C1CCN(c2ccc(C)c(C)c2)CC1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADRB1 P08588 1/20 0.58
▸ MAPT P10636 4/20 0.45
▸ GAA P10253 3/20 0.45
▸ HTR7 P34969 1/20 0.41
▸ TRPV1 Q8NER1 1/20 0.40
▸ DRD2 P14416 2/20 0.40
▸ DRD3 P35462 2/20 0.40
▸ DPP4 P27487 1/20 0.40
▸ LMNA P02545 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ RAD52 P43351 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ DRD4 P21917 3/20 0.39
▸ ACACB O00763 1/20 0.38
▸ HPGD P15428 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2092625 0.83 ADRB1 (0.59) ADRB1MAPTGAAHTR7DPP4
SCHEMBL28225140 0.79 ADRB1 (0.53) ADRB1MAPTGAALMNATP53
SCHEMBL3539353 0.78 ADRB1 (0.68) ADRB1MAPTGAAHTR7LMNA
SCHEMBL24140572 0.78 ADRB1 (0.68) ADRB1MAPTGAAHTR7LMNA
SCHEMBL22754166 0.77 L3MBTL3 (0.68) ADRB1
SCHEMBL8320341 0.77 ADRB1 (0.61) ADRB1MAPTGAAHTR7DRD2
SCHEMBL22818552 0.76 ADRB1 (0.66) ADRB1MAPTGAAHTR7LMNA
SCHEMBL8390975 0.76 ADRB1 (0.66) ADRB1MAPTGAAHTR7LMNA
SCHEMBL5800611 0.76 NOTUM (0.55) ADRB1MAPTGAATRPV1HPGD
SCHEMBL8320347 0.75 ADRB1 (0.63) ADRB1MAPTGAATP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 — — US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 — — EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 ADRB1 189/4885MAPT 4299/4885GAA 3982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback